Observational studyRevista medica del Instituto Mexicano del Seguro Social2023
[Diagnostic performance of the FINDRISC questionnaire to identify insulin resistance in adults].
Observational study in Revista medica del Instituto Mexicano del Seguro Social, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Comment on the article: "Diagnostic performance of the FINDRISC questionnaire to identify insulin resistance in adults"].Revista medica del Instituto Mexicano del Seguro Social · 2025Article
- [Answer to "Comment on the article: "Diagnostic performance of the FINDRISC questionnaire to identify insulin resistance in adults""].Revista medica del Instituto Mexicano del Seguro Social · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Insulin resistance (IR) is a state prior to the development of type 2 diabetes (T2D) and it is reversible with lifestyle modification. However, it is underdiagnosed due to the difficulty in its measurement. Objective: To evaluate the diagnostic performance of the FINDRISC questionnaire to identify IR. Material and methods: An analytical cross-sectional study was performed in adults aged 20 to 60 years without previous diagnosis of T2D. Those using steroids and pregnant women were excluded. IR was diagnosed through the Triglycerides/glucose index. A ROC curve was used to establish the cut-off point for the diagnosis of IR. Sensitivity, specificity, predictive values and likelihood ratios were calculated. Risk measurement for IR was performed with the FINDRISC instrument. Results: A total of 253 participants were included, with a prevalence of IR of 60.8%. The area under the curve of the FINDRISC instrument was 0.813 (95% confidence interval [95% CI] 0.759-0.865), with a cut-off point of 8. Sensitivity was 94.8% and specificity was 48.5%, positive predictive value was 74% and negative 86%, with a positive likelihood ratio of 1.84 and a negative of 0.11. Conclusions: The FINDRISC instrument is a useful screening tool to identify subjects with IR at the first level of care. A score ≥ 8 identifies subjects with IR.
Indexed as
Identifiers
36542467PMC10395935What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.